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Abstract
Background: High dose oral ascorbic acid substantially improved myelination and locomotor
function in a Charcot-Marie-Tooth type 1A mouse model. A phase II study was warranted to
investigate whether high dose ascorbic acid also has such a substantial effect on myelination in
Charcot-Marie-Tooth type 1A patients and whether this treatment is safe.
Methods: Patients below age 25 years were randomly assigned to receive placebo or ascorbic acid
(one gram twice daily) in a double-blind fashion during one year. The primary outcome measure
was the change over time in motor nerve conduction velocity of the median nerve. Secondary
outcome measures included changes in minimal F response latencies, compound muscle action
potential amplitude, muscle strength, sensory function, Charcot-Marie-Tooth neuropathy score,
and disability.
Results: There were no significant differences between the six placebo-treated (median age 16
years, range 13 to 24) and the five ascorbic acid-treated (19, 14 to 24) patients in change in motor
nerve conduction velocity of the median nerve (mean difference ascorbic acid as opposed to
placebo treatment of 1.3 m/s, confidence interval -0.3 to 3.0 m/s, P = 0.11) or in change of any of
the secondary outcome measures over time. One patient in the ascorbic acid group developed a
skin rash, which led to discontinuation of the study medication.
Conclusion: Oral high dose ascorbic acid for one year did not improve myelination of the median
nerve in young Charcot-Marie-Tooth type 1A patients. Treatment was relatively safe.
Trial registration: Current Controlled Trials ISRCTN56968278, ClinicalTrials.gov
NCT00271635.
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Background
Charcot-Marie-Tooth type 1A (CMT1A), also known as
Hereditary Motor and Sensory Neuropathy type Ia
(HMSN Ia), is the most prevalent hereditary peripheral
neuropathy (approximately 1:5,000 people) [1]. CMT1A
is an autosomal dominant disease, most often caused by
a 1.5 Mb duplication on chromosome 17, giving rise to
three copies of the peripheral myelin protein 22 (PMP22)-
gene. Histologically, there are signs of dysmyelination, of
active de- and remyelination especially during the first
years of life, and of axonal loss [2,3]. The conduction
velocities of the peripheral nerves are slow very early in
life and after the age of approximately five years longitu-
dinal data show that the conduction velocities remain
fairly stable, consistent with a fairly constant myelination
status [4-7]. Compound muscle action potential (CMAP)
amplitudes as recorded from distal leg muscles are found
to decrease during the first two decades of life, indicating
increasing secondary axonal dysfunction [8]. This increas-
ing axonal dysfunction is responsible for the development
of symptoms and signs of predominantly distal muscle
weakness, atrophy, and sensory abnormalities, in the legs
more than the arms [8,9]. One of the factors determining
the severity of secondary axonal dysfunction is the degree
of initial abnormal myelination [9]. Until now, therapy is
symptomatic and aims at maintaining functional abilities
and learning compensation mechanisms. Therapy
directed at restoration of myelination is expected to be
most beneficial in young patients, as more secondary
axonal dysfunction may be prevented than in older
patients [7].
An in vitro study showed that high doses of ascorbic acid
may repress PMP22 gene expression by acting on intracel-
lular cyclic adenosine monophosphate levels and ade-
nylate cyclase activity [10]. This may explain why in a
mouse model for CMT1A, in which the animals over-
express human PMP22, ascorbic acid induced remyelina-
tion and improved locomotor functioning [11]. Mice
aged two to four months treated with orally administered
high doses of ascorbic acid once a week during three
months showed increased percentages of myelinated
fibres (from 25 to 70%) and increased myelin sheath
thickness in the sciatic nerves with fairly normal g ratios
[11]. Electrophysiological data have not been published
in this study, but the substantial improvements of myeli-
nation parameters in the histological analysis suggested
that the same may hold true for nerve conduction. Nerve
conduction velocities are a non-invasive surrogate marker
for myelination which are relatively easily obtainable in
longitudinal studies in CMT1A patients [4-7]. For this rea-
son, we initiated a proof of principle study to investigate
whether ascorbic acid also has a substantial effect on mye-
lination in CMT1A patients. This may in turn also have a
positive effect on axonal function and in that respect on
clinical impairments and disability. Therefore, we per-
formed a single-centre, randomised, double-blinded,
phase II study comparing a high dose ascorbic acid with a
placebo during one year to assess the effects of ascorbic
acid on myelination and its safety in young CMT1A
patients.
Methods
CMT1A patients were recruited from the outpatient
department of neurology at the Academic Medical Centre
(AMC), University of Amsterdam and via the Dutch Neu-
romuscular Patient Association (Vereniging Spierziekten
Nederland). They were assessed for eligibility between
December 2005 and June 2006. Inclusion criteria were:
DNA-proven diagnosis of CMT1A; age range 12 to 25
years; clinically affected status defined as muscle weakness
of at least the foot dorsiflexors. Exclusion criteria were:
other known disease or medication that may cause a neu-
ropathy, chronic alcohol abuse, regular use of ascorbic
acid before the study, clinical or ultrasound signs of neph-
rolithiasis, reduced glomerular filtration rate, iron over-
load, no regular dental control at the dentist, pregnancy or
active pregnancy wish for women, psychiatric co-morbid-
ity which may influence compliance, reluctance to
undergo nerve conduction studies, a low CMAP ampli-
tude of the abductor pollicis brevis muscle (negative peak
< 0.5 mV) hindering proper determination of the motor
nerve conduction velocity (MNCV) of the median nerve.
The local medical ethics committee approved the study
protocol. All patients, and where appropriate the parents,
gave written informed consent to participate in the study.
This study has been registered in ClinicalTrials.gov,
number NCT00271635, and in Current Controlled Trials,
number ISRCTN56968278.
Procedure
Eligible patients were randomly allocated to oral ascorbic
acid or placebo. The pharmacist, who did not have any
further role in the study, generated a computerized rand-
omization sequence. Participants and investigators were
unaware of the treatment assignment. The tolerable upper
intake level of ascorbic acid for adults is 2 g/day, for chil-
dren 14 to 18 years 1.8 g/day, and for children 9 to 13
years 1.2 g/day. A higher intake is acceptable with clinical
monitoring [12]. Treatment was administered in a dou-
ble-blind fashion for 12 months and was either four cap-
sules containing 250 mg ascorbic acid twice daily (daily
dose: 2 g), or four capsules containing placebo with iden-
tical size, colour, shape, and taste twice daily. Patients
were assessed for all outcome measures at baseline and at
6 and 12 months follow-up by the same investigator
(C.V.). Given the explorative nature of the phase II study,
we used a primary outcome measure at the impairment
level to test the efficacy of ascorbic acid; the mean changeBMC Medicine 2009, 7:70 http://www.biomedcentral.com/1741-7015/7/70
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over time of the MNCV of the median nerve at 12 months
follow-up, which we consider the best non-invasive surro-
gate marker for changes in myelination [9,13,14]. At the
non-dominant side of the body large surface recording
electrodes (2.0 × 2.6 cm) were attached over the surface of
the abductor pollicis brevis muscle at standardised sites
defined by anatomical landmarks. Temperature was
maintained between 32 and 34°C as measured at distal
recording sites. The median nerve was stimulated at the
wrist and elbow, and the MNCV was calculated. The sec-
ondary outcomes included changes over time at 12
months of other measures at the impairment and disabil-
ity level. The mean change over time of the minimal F
response latency of the median nerve was an additional
non-invasive surrogate marker for changes in myelina-
tion. The mean change over time of the CMAP amplitude
(negative peak) recorded from the abductor pollicis brevis
muscle was a non-invasive surrogate marker for changes
in axonal function [9,14]. The mean change over time of
strength of the three point grip and the foot dorsiflexors as
assessed with hand-held dynamometry were indicators
for changes in arm and leg strength, respectively [15,16].
The median change over time of the Inflammatory neu-
ropathy cause and treatment sensory sum score (ISS)
assessed changes in sensory function [17]. It comprises
vibration and pinprick sense plus a two-point discrimina-
tion value and ranges from 0 (normal sensation) to 20
(maximum sensory deficit). The median change over time
of the Charcot-Marie-Tooth neuropathy score (CMTNS)
assessed changes in an overall composite impairment
score [18]. It comprises items from history, clinical and
electrophysiological investigations and ranges from 0 (no
deficit) to 36 (maximal deficit). The mean change over
time in the AMC linear Disability Score (ALDS) was an
indicator for changes in disability [19]. It ranges from 0
(dead) to 100 (fully able). The median change over time
of the overall disability sum score (ODSS) was another
indicator for changes in disability [20]. It comprises arm
and leg items and ranges from 0 (no disability) to 12
(maximum disability). Indicators for changes in func-
tional performance were the mean change over time of the
time needed for the nine hole peg test [16,21], and of the
time needed for the 50 m walking test, which we decided
would be more sensitive to change than the 10 m walking
test [16]. Motor unit number estimation of the thenar
muscles was determined in the context of another study
[22], and will be reported separately.
Adverse events and laboratory values were monitored
every three months or more often if necessary, and were
reviewed by an independent Data Safety Monitoring
Board. A repeat ultrasound of the kidneys was done at 12
months. Capsule counts were performed every three
months to monitor treatment adherence. At the end of the
study the success of blinding was evaluated by asking the
participant and the investigator separately which trial
medication they thought the participant had used (pla-
cebo, ascorbic acid or 'I really don't know').
Statistical analysis
We deduced from the substantial improvement in histo-
logical myelination parameters of the animal experimen-
tal study that at least a mean improvement of the MNCV
of the median nerve of 10 m/s should be detectable in the
ascorbic acid-treated group as opposed to the placebo-
treated group. Such an improvement was considered
potentially clinically meaningful. In a previous study on
46 CMT1A patients, the mean MNCV of the median nerve
was found to be 23 m/s with a standard deviation (SD) of
5.3 [9]. As there were no SDs for possible changes in
MNCV, we conservatively used SDs of 5.3 to calculate
group sizes. Six patients per group were required to detect
a difference of 10 m/s with 80% power and a two-sided
alpha level of 0.05 using the unpaired t test. Randomised
patients with at least one follow-up measure of the pri-
mary outcome were analyzed according to the intention-
to-treat principle. In case of incomplete data, we used the
last observation carried forward approach. The mean or
median change scores from baseline to final follow-up of
the patients receiving ascorbic acid and those receiving
placebo were presented together with the differences in
these change scores between the treatment groups using
unpaired t test or Mann-Whitney U test, when appropri-
ate. Statistical uncertainty was quantified via correspond-
ing 95% confidence intervals for the differences in change
scores between the treatment groups. Additionally, we
analysed the MNCV of the median nerve at follow-up,
given the MNCV of the median nerve at baseline, using
analysis of covariance to evaluate the effect of being
treated either with ascorbic acid or placebo [23]. For the
analysis of covariance we presented the averaged differ-
ence together with the 95% confidence interval. All anal-
yses were done with SPSS 15.0 for Windows (SPSS Inc.
Chicago, Illinois, USA).
Results
Sixteen of the 29 patients initially screened for the study
did not meet the inclusion criteria (Figure 1). Eight
patients refused to participate for various reasons. Four
patients, who responded via the patients' association, had
another form of CMT. Four patients already used supple-
mental ascorbic acid. From the randomised 13 patients
one female participant in the placebo group aged 18 years
with a baseline MNCV of the median nerve of 21 m/s was
excluded during the study because of a pregnancy wish
before the six months' assessment. One male participant
in the ascorbic acid group aged 21 years with a baseline
MNCV of the median nerve of 16 m/s developed a skin
rash after the first days of study medication use which dis-
appeared after stopping the study medication.BMC Medicine 2009, 7:70 http://www.biomedcentral.com/1741-7015/7/70
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Flow diagram of the trial Figure 1
Flow diagram of the trial.
Assessed for eligibility  (n = 29) 
Excluded  (n = 16) 
Not meeting inclusion criteria (n = 8) 
No CMT1A (n = 4)
Already ascorbic acid (n = 4)  
  Refused to participate (n = 8) 
Analysed (n = 5) 
Lost to follow-up (n = 0) 
Discontinued intervention (n = 1) 
Rash after intake of 
medication
Allocated to ascorbic acid  
(n = 6) 
Received allocated intervention 
(n = 6) 
Lost to follow-up (n = 0) 
Discontinued intervention (n = 1) 
Pregnancy wish shortly after start 
of study medication 
Allocated to placebo 
(n = 7) 
Received allocated intervention 
(n = 7) 
     
Analysed (n = 6) 
Allocation
Efficacy
analysis
Follow-up
Enrolment
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Baseline characteristics of the 11 patients in which at least
one primary outcome measure during follow-up was
obtained are described in Table 1. Both groups were fairly
similar with regard to baseline characteristics. In each
group, one participant had a follow-up until six months:
in the placebo group one participant discontinued medi-
cation due to gastrointestinal complaints and in the ascor-
bic acid group one participant failed to attend the
outpatient clinic afterwards. All the other participants had
a follow-up until 12 months.
The MNCVs of the median nerve over time of individual
participants in the placebo and ascorbic acid treated
groups are shown in figure 2A and 2B, respectively. Table
2 summarizes the primary and secondary outcome meas-
ures. The mean change in MNCV of the median nerve over
time was not different between the treatment groups (P =
0.11). Additionally, analysis of covariance showed a non-
significant averaged difference of 1.3 m/s (confidence
interval -0.4 to 2.9, P = 0.12) in favour of the ascorbic acid
as opposed to the placebo treated group, given the
MNCVs of the median nerve at baseline. None of the sec-
ondary outcome measures showed significant score
changes.
Adverse events were registered for all randomised partici-
pants (n = 13) who were allocated trial medication. In the
placebo group three out of the seven included participants
had gastrointestinal complaints during the study, while in
the ascorbic acid group one of the six participants had an
adverse event. In the placebo group one female partici-
pant had severe complaints of cramps and diarrhoea to
such an extent that she discontinued the study medication
after just six months, one participant had feelings of nau-
sea during the nine months and 12 months visits, and one
participant had feelings of nausea and cramps at three
months. The latter individual was excluded from the study
because of a pregnancy wish just after three months (Fig-
ure 1). In the ascorbic acid group one adult participant
developed a skin rash after the first days of treatment (see
also Figure 1). This was interpreted as an allergic reaction;
the rash disappeared after stopping the study medication.
None of the 13 participants complained about renal colic
or reported tooth problems. There were no relevant
changes in laboratory values. None of the nine partici-
pants who attended at 12 months had signs of kidney
stones or renal disorders on a repeat ultrasound of the kid-
neys. Of the participants who left the study before 12
months no repeat ultrasound was made.
Counts of returned capsules showed that the six placebo
treated participants and the five ascorbic acid treated par-
ticipants both used 88% of the capsules on average during
the study period. In the ascorbic acid group three out of
five participants did not know what treatment they were
using, one correctly and one incorrectly identified group
assignment. In the placebo group four out of six partici-
pants did not know their treatment allocation and two
correctly identified group assignment. The investigator
did not know treatment allocation of any participant.
Forced guessing corresponded with correct group alloca-
tion in three out of five in the ascorbic acid group and four
out of six in the placebo group. None of the participants
reported the intake of supplemental ascorbic acid during
the study period.
Discussion
In this phase II study high dose ascorbic acid given during
one year to young CMT1A patients did not lead to a posi-
tive predefined effect on myelination, assessed as a differ-
Table 1: Baseline characteristics of study participants described for primary and secondary outcome measures.
Placebo
(n = 6)
Ascorbic acid
(n = 5)
Male/Female (numbers) 2/4 3/2
Age (years)b 16 (13-24) 19 (14-24)
Median nerve MNCV (m/s)a 17.9 (6.0) 17.2 (1.7)
Median nerve minimal F response latency (ms)a 83.8 (28.0)* 77.1 (10.6)
CMAP amplitude abductor pollicis brevis muscle (mV)a 3.9 (1.1) 4.0 (1.2)
Three point grip (N)a 50.9 (14.4) 73.8 (24.7)
Foot dorsiflexors (N)a 79.5 (14.0) 91.1 (26.9)
ISSb 2 (0-8) 3 (1-6)
CMTNSb 10 (7-20) 13 (7-17)
ODSSb 3 (2-4) 2 (2-4)
ALDSa 86.8 (6.5) 89.0 (0.5)
Nine hole peg test (s)a 26.3 (6.6) 23.5 (1.8)
50 m walking (s)a 31.9 (2.0) 29.2 (3.2)
a Mean (standard deviation) bMedian (range) * n = 5
Abbreviations: ALDS = Academic Medical Centre linear disability score; CMAP = Compound muscle action potential; CMTNS = Charcot-Marie-
Tooth neuropathy score; ISS = inflammatory neuropathy cause and treatment sensory sum score; MNCV = motor nerve conduction velocity; 
ODSS = overall disability sum scoreBMC Medicine 2009, 7:70 http://www.biomedcentral.com/1741-7015/7/70
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ence of the MNCV of the median nerve of 10 m/s between
the ascorbic acid- and placebo-treated patients. We found
a non-significant difference in mean MNCV change scores
between ascorbic acid as opposed to placebo treatment of
1.3 m/s with an upper limit of the confidence interval of
3 m/s. Neither could we demonstrate significant effects of
ascorbic acid for any of the secondary outcome measures,
including minimal F response latency of the median
nerve, CMAP amplitude, muscle strength, sensory func-
tion and disability. The treatment consisting of 2 g per day
during one year was relatively safe, although there was
one serious adverse event: one patient in the ascorbic acid
group developed a rash, which led to discontinuation of
the study medication. A delayed type hypersensitivity to
ascorbic acid has been seldom reported [24].
The rationale for our study was derived from the results of
a study, showing a robust effect of high doses ascorbic
acid on myelination in a PMP22 over-expressing mouse
model [11]. To our knowledge these results have not been
reproduced in the same or other animal models. A 12-
month randomised, double-blind, placebo controlled
trial in 81 CMT1A children aged 2 to 16 years with com-
parable high-dose oral ascorbic acid (30 mg/kg/day) did
not show an improvement on motor nerve conduction
velocity, CMAP amplitudes or functional abilities but
treatment was safe and well tolerated [25]. A two-year
non-randomised open-label pilot study compared a
group of 12 adult patients starting with 5 g of ascorbic acid
daily with a group of 10 age-matched untreated patients
[26]. Five out of 12 treated patients (42%) tolerated 5 g
daily for the entire study period; two (17%) were able to
finish the study period after lowering the dose to 2.5 g
daily; five (42%) discontinued treatment, mainly due to
gastrointestinal side effects. Nerve conduction velocities,
CMAP amplitudes and the CMTNS did not improve over
time when either the whole group of 12 patients initially
receiving ascorbic acid, or the five patients who received 5
g daily during the entire study period, were compared
with the control group [26]. This study showed that
adverse events limit the tolerable doses in CMT1A patients
and did not provide evidence for the effectiveness of doses
as high as 5 g daily.
The discrepancy in effectiveness of ascorbic acid between
the mouse model and humans may have several explana-
tions. PMP22 gene over-expression may be higher in the
mouse model, as this model has seven extra copies of the
human PMP22 gene, while human patients only have one
extra copy. Thus, myelination is more severely affected in
the mouse model, as indicated by a considerably lower
mean MNCV in the mouse model as compared to that in
CMT1A patients [9,27]. Whether this difference in myeli-
nation of the peripheral nerves at outset evokes a different
response to high dose ascorbic acid is unknown. The effec-
tiveness of PMP22 gene repression in humans may be too
small to notice a clear effect on myelination. Another
explanation may be the fact that ascorbic acid metabolism
in humans is distinct from that in mice. Humans derive
ascorbic acid entirely from dietary sources, while mice are
able to synthesize ascorbic acid [28]. There may also be a
difference between mice and humans with regard to the
uptake of ascorbic acid or its metabolic intermediates at
the tissue and cellular level, leading to different effects.
Table 2: Primary and secondary treatment outcomes according to assigned treatment.
Placebo
(n = 6)
Ascorbic acid
(n = 5)
Change Change Difference P value
Median nerve MNCV (m/s)a -0.8 (0.9) 0.5 (1.5) 1.3 (-0.3-3.0) 0.11
Median nerve minimal F response latency (ms)a 3.5 (8.0)* -5.6 (4.4) -9.1 (-18.5-0.3) 0.06
CMAP amplitude abductor pollicis brevis muscle (mV)a -0.02 (0.9) -0.2 (0.8) -0.1 (-1.3 -1.1) 0.79
Three point grip (N)a -3.0 (9.2) 3.4 (9.0) 6.4 (-6.1-18.9) 0.28
Foot dorsiflexors (N)a -5.1 (17.6) 0.6 (15.6) 5.6 (-17.3-28.6) 0.59
ISSb 0 (-4-1) -2 (-2-1) -2 (-2-2) 0.30
CMTNSb 1 (-5-4) -2 (-3-1) -3 (-6-3) 0.14
ODSSb 0 (0-1) 0 (-2-0) 0 (-2-0) 0.18
ALDSa 1.0 (3.7) 0.3 (0.4) -0.6 (-4.5-3.2) 0.30
Nine hole peg test (s)a -3.5 (2.8) -2.0 (1.8) 1.5 (-1.8-4.8) 0.32
50 m walking (s)a -0.6 (1.9) -0.9 (1.8) -0.3 (-2.9-2.2) 0.77
Change = a mean (standard deviation) or bmedian (range) change scores from baseline to final follow-up. Difference = difference in a mean or b 
median change scores (95% confidence interval) of the patients receiving ascorbic acid and those receiving placebo. P-value = P-value for a the 
unpaired t test (equal variances assumed) or bthe Mann-Whitney U test. * n = 5
Abbreviations: ALDS = Academic Medical Centre linear disability score; CMAP = compound muscle action potential; CMTNS = Charcot-Marie-
Tooth neuropathy score; ISS = inflammatory neuropathy cause and treatment sensory sum score; MNCV = motor nerve conduction velocity; 
ODSS = overall disability sum scoreBMC Medicine 2009, 7:70 http://www.biomedcentral.com/1741-7015/7/70
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Motor nerve conduction velocities of the median nerve over time Figure 2
Motor nerve conduction velocities of the median nerve over time. Motor nerve conduction velocity (MNCV) of the 
median nerve (m/s) over time (months) in the placebo (A) and ascorbic acid (B) treated participants. Each connected symbol 
corresponds with an individual participant.
0369 1 2
Time (months)
0
5
10
15
20
25
30
M
N
C
V
m
e
d
i
a
n
 
n
e
r
v
e
(
m
/
s
)
9
9
3
3 3
4
4
4
: : :
5
5 5
6
6
6
A
0369 1 2
Time (months)
0
5
10
15
20
25
30
M
N
C
V
m
e
d
i
a
n
 
n
e
r
v
e
(
m
/
s
)


 
 
 
 
! ! !
#
#
#
BBMC Medicine 2009, 7:70 http://www.biomedcentral.com/1741-7015/7/70
Page 8 of 9
(page number not for citation purposes)
Some strengths of this study should be addressed. To
answer the question whether the substantial positive
effects of high dose ascorbic acid on myelination in a
CMT1A mouse model may be reproducible in humans a
non-invasive surrogate marker for myelination (MNCV of
the median nerve) was chosen as primary efficacy out-
come measure because this measure reflects the intended
biological effect (induction of remyelination) as close as
possible. MNCVs are validated measures [14] and com-
monly used as a non-invasive surrogate marker for myeli-
nation in CMT1A studies [4-7]. We assumed that a follow-
up of one year should be long enough to detect at least
any indication of remyelination. Theoretically, this remy-
elination should secondarily lead to a decrease in axonal
dysfunction. This introduces more uncertain factors like
the capacity of remyelination to prevent axonal dysfunc-
tion and even to restore axonal function over time in
CMT1A patients. This is why parameters like the compos-
ite CMTNS were included as secondary outcome meas-
ures. It is of note that the CMTNS does not include any
measure of myelination, and thus was considered not to
be suitable as the primary outcome measure in our study.
Finally, we included young patients who may benefit
most from treatment, as more axonal dysfunction may be
prevented than in older patients.
Some limitations of this study should also be addressed.
In retrospect, the conversion from the improvement of
myelination parameters in the histological analysis in the
mouse study [11] to the intended improvement in
humans, 10 m/s for the MNCV of the median nerve, may
have been too optimistic. In CMT1A there are no data
available about the minimal increase of MNCVs giving
rise to a clinically meaningful secondary effect on axonal
function and more importantly on disability. However,
we hypothesized that a 10 m/s increase was potentially
clinically relevant and we performed a power calculation
based on this, leading to small numbers of patients in
each group. Since our goal was to find out whether high
dose ascorbic acid had the same substantial effect on mye-
lination as had been found in the animal study, we
decided to carry out a small proof of principle study first.
The non-significant difference in mean MNCV change
scores between ascorbic acid and placebo treated patients
we found is in accordance with the non-significant differ-
ence in a randomised controlled trial in a much larger
group of patients [25] and is in our opinion too little to
have enough potential clinical relevance to initiate studies
with larger numbers of patients, although we are aware
that these are under way [29]. Moreover, the difference we
found may well be due to normal measurement variation
inherent to conduction studies as suggested by the fact
that the major part of this modest difference was due to a
decrease in MNCV over time in the placebo group and not
to an increase in MNCV over time in the ascorbic acid
group.
Conclusion
This randomised double-blind, placebo-controlled, phase
II trial with high dose ascorbic acid (2 g per day) for one
year in children and young adults with CMT1A was initi-
ated as a proof of principle study but did not show an
improvement of myelination in the median nerve. In our
hands treatment with 2 g per day during one year was rel-
atively safe. Thus, evidence is accumulating that ascorbic
acid does not have the same robust positive effect on mye-
lination and functional abilities as was shown in the
PMP22 over-expressing mouse model [11] in neither child
nor (young) adult CMT1A patients [25,26].
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